Status: Recruiting
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.
Participants needed: 480
Trial details
Phase: Phase 2Age: 6-71Biological sex: AllType: InterventionalSponsor: Shanghai Reinovax Biologics Co.,LTDUpdated: Jan 16, 2026Locations: 7
Eligibility criteria
Healthy subjects aged 2 months (minimum 6 weeks) and 7-71 months, whose guardian... [+2]
Subjects who have received any type of pneumococcal vaccine prior to enrollment,... [+17]